[Skip to Content]
[Skip to Content Landing]
Article
March 19, 1982

Surveillance of Bromocriptine in Pregnancy

Author Affiliations

From the Drug Monitoring Center, Clinical Research Department, Pharmaceutical Division, Sandoz Ltd, Basel, Switzerland.

JAMA. 1982;247(11):1589-1591. doi:10.1001/jama.1982.03320360039028
Abstract

Information was collected on the outcome of 1,410 pregnancies in 1,335 women to whom bromocriptine mesylate (Parlodel) had been given, primarily in the early weeks of pregnancy. These pregnancies resulted in 197 early terminations (14%) (including 25 induced abortions [1.8%]) and in 1,213 births (86%). The incidence rate of spontaneous abortions (11.1%), extrauterine pregnancies (0.9%), and minor (2.5%) and major (1.0%) malformations is comparable with that quoted for normal populations, and the incidence of twin pregnancies (1.8%) is slightly but not significantly raised, if correction is made for concomitant therapy with other agents inducing ovulation. The data suggest that the intake of bromocriptine during pregnancy is not associated with an increased risk to the fetus.

(JAMA 1982;247:1589-1591)

×